## Alexander Kretschmer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5511698/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. European Urology Oncology, 2022, 5, 285-295.	2.6	4
2	Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1417-1428.	3.3	13
3	Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence. Current Opinion in Urology, 2022, 32, 69-84.	0.9	6
4	Clinical Implication of Borderline CT-Morphological Metastatic Spread in Bladder Cancer: What You See Is Not Always What You Got. Urologia Internationalis, 2022, , 1-10.	0.6	0
5	Molecular Mechanisms Related with Oligometastatic Prostate Cancer—Is It Just a Matter of Numbers?. Cancers, 2022, 14, 766.	1.7	2
6	Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210819.	1.4	12
7	Multicentric comparative analysis of Retzius versus Retzius sparing robotic assisted simple prostatectomy in the management of large prostate glands. Scandinavian Journal of Urology, 2022, 56, 119-125.	0.6	1
8	Health-related quality of life as a prognostic indicator of biochemical recurrence free survival in high-risk prostate cancer patients following radical prostatectomy Journal of Clinical Oncology, 2022, 40, 235-235.	0.8	1
9	The prognostic impact of preoperative health-related quality life on bladder cancer-specific survival in patients treated with radical cystectomy Journal of Clinical Oncology, 2022, 40, 475-475.	0.8	0
10	Baseline Health-related Quality of Life Predicts Bladder Cancer–specific Survival Following Radical Cystectomy. European Urology Focus, 2022, 8, 1659-1665.	1.6	6
11	Long-term Health-related Quality of Life (HRQOL) After Radical Cystectomy and Urinary Diversion - A Propensity Score-matched Analysis. Clinical Genitourinary Cancer, 2022, 20, e283-e290.	0.9	5
12	Feasibility of [68Ca]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3571-3580.	3.3	12
13	Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer—Current State and Future Perspectives. Cancers, 2022, 14, 147.	1.7	2
14	Accuracy and prognostic value of radiological lymph node features in variant histologies of bladder cancer. World Journal of Urology, 2022, 40, 1707-1714.	1.2	4
15	Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel—A Real-world Data Assessment. European Urology Focus, 2021, 7, 1308-1315.	1.6	3
16	A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?. European Urology Oncology, 2021, 4, 745-754.	2.6	17
17	Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. European Urology Focus, 2021, 7, 742-751.	1.6	19
18	Impact of previous transurethral prostate surgery on health-related quality of life after radical prostatectomy: Does the interval between surgeries matter?. World Journal of Urology, 2021, 39, 1431-1438.	1.2	3

#	Article	IF	CITATIONS
19	First Clinical Results for PSMA-Targeted α-Therapy Using <sup>225</sup> Ac-PSMA-I&T in Advanced-mCRPC Patients. Journal of Nuclear Medicine, 2021, 62, 669-674.	2.8	87
20	Radical cystectomy for locally advanced urothelial carcinoma of the urinary bladder: Health-related quality of life, oncological outcomes and predictors for survival. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 299.e15-299.e21.	0.8	3
21	Five-Year Results of a Prospective Multicenter Trial: AdVance XP for Postprostatectomy-Incontinence in Patients with Favorable Prognostic Factors. Urologia Internationalis, 2021, 105, 421-427.	0.6	10
22	Adherence to guidelines in the management of urolithiasis: are there differences among distinct patient care settings?. World Journal of Urology, 2021, 39, 3079-3087.	1.2	2
23	Routine application of next-generation sequencing testing in uro-oncology—Are we ready for the next step of personalised medicine?. European Journal of Cancer, 2021, 146, 1-10.	1.3	5
24	A matter of size? Healthâ€related quality of life after radical prostatectomy for patients with giant prostates. Prostate, 2021, 81, 443-451.	1.2	2
25	Salvage cystectomy and ileal conduit urinary diversion as a lastâ€line option for benign diseases—perioperative safety and postoperative healthâ€related quality of life. Neurourology and Urodynamics, 2021, 40, 1154-1164.	0.8	5
26	Radical Prostatectomy: Sequelae in the Course of Time. Frontiers in Surgery, 2021, 8, 684088.	0.6	4
27	Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients. Frontiers in Oncology, 2021, 11, 663631.	1.3	7
28	Patient-Reported and Oncological Outcomes of Salvage Therapies for PSMA-Positive Nodal Recurrent Prostate Cancer: Real-Life Experiences and Implications for Future Trial Design. Frontiers in Oncology, 2021, 11, 708595.	1.3	3
29	Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer. Radiation Oncology, 2021, 16, 125.	1.2	17
30	Focal Therapy for Prostate Cancer: Complications and Their Treatment. Frontiers in Surgery, 2021, 8, 696242.	0.6	13
31	Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time?. Frontiers in Surgery, 2021, 8, 691473.	0.6	5
32	A realâ€world comparison of docetaxel versus abiraterone acetate for metastatic hormoneâ€sensitive prostate cancer. Cancer Medicine, 2021, 10, 6354-6364.	1.3	7
33	Has the COVID-19 outbreak changed the way we are treating prostate cancer? An EAU – YAU Prostate Cancer Working Group multi-institutional study. Central European Journal of Urology, 2021, 74, 362-365.	0.2	3
34	Combined Open Prostatectomy and Kidney Surgery: Feasibility and 12-Month Outcome. Research and Reports in Urology, 2021, Volume 13, 815-821.	0.6	0
35	Health-Related Quality of Life following Cytoreductive Radical Prostatectomy in Patients with De-Novo Oligometastatic Prostate Cancer. Cancers, 2021, 13, 5636.	1.7	9
36	Midterm Health-related Quality of Life After Radical Cystectomy: A Propensity Score–matched Analysis. European Urology Focus, 2020, 6, 704-710.	1.6	20

#	Article	IF	CITATIONS
37	Preoperative Thrombocytosis in Patients Undergoing Radical Cystectomy for Urothelial Cancer of the Bladder: An Independent Prognostic Parameter for an Impaired Oncological Outcome. Urologia Internationalis, 2020, 104, 36-41.	0.6	12
38	Bladder Cancer Stage Development, 2004-2014 in Europe Compared With the United States: Analysis of European Population-based Cancer Registries, the United States SEER Database, and a Large Tertiary Institutional Cohort. Clinical Genitourinary Cancer, 2020, 18, 162-170.e4.	0.9	12
39	Long-Term Follow-Up and Oncological Outcome of Patients Undergoing Radical Cystectomy for Bladder Cancer following an Enhanced Recovery after Surgery (ERAS) Protocol: Results of a Large Randomized, Prospective, Single-Center Study. Urologia Internationalis, 2020, 104, 55-61.	0.6	25
40	Benefits and Limitations of Transurethral Resection of the Prostate Training With a Novel Virtual Reality Simulator. Simulation in Healthcare, 2020, 15, 14-20.	0.7	9
41	Prognostic value of pretreatment inflammatory markers in variant histologies of the bladder: is inflammation linked to survival after radical cystectomy?. World Journal of Urology, 2020, 39, 2537-2543.	1.2	10
42	Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate. European Urology Focus, 2020, 7, 1247-1253.	1.6	7
43	Patient Selection in Surgical Centers of Expertise in the Treatment of Patients with Moderate to Severe Male Urinary Stress Incontinence. Urologia Internationalis, 2020, 104, 902-907.	0.6	4
44	Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer. Molecular Cancer Therapeutics, 2020, 19, 2210-2220.	1.9	8
45	Is It Safe to Offer Radical Cystectomy to Patients above 85 Years of Age? A Long-Term Follow-Up in a Single-Center Institution. Urologia Internationalis, 2020, 104, 975-981.	0.6	8
46	Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. European Urology Oncology, 2020, 3, 565-581.	2.6	46
47	Fixed or adjustable sling in the treatment of male stress urinary incontinence: results from a large cohort study. Translational Andrology and Urology, 2020, 9, 1099-1107.	0.6	5
48	Secondary Sling Implantation after Failure of Primary Surgical Treatment for Male Stress Urinary Incontinence: A Retrospective Study. Urologia Internationalis, 2020, 104, 625-630.	0.6	1
49	Impact of Routine Laboratory Parameters in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Long-Term Follow-Up. Urologia Internationalis, 2020, 104, 551-558.	0.6	12
50	Health-related quality of life after open and robot-assisted radical prostatectomy in low- and intermediate-risk prostate cancer patients: a propensity score-matched analysis. World Journal of Urology, 2020, 38, 3075-3083.	1.2	9
51	Retropubic vs transobturator Argus adjustable male sling: Results from a multicenter study. Neurourology and Urodynamics, 2020, 39, 987-993.	0.8	7
52	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. European Urology, 2020, 78, 661-669.	0.9	74
53	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. European Urology, 2020, 78, 779-782.	0.9	16
54	High/lowâ€volume center experience predicts outcome of AMS 800 in male stress incontinence: Results of a large middle European multicenter case series. Neurourology and Urodynamics, 2020, 39, 1856-1861.	0.8	9

#	Article	IF	CITATIONS
55	PSMA-positive nodal recurrence in prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 637-646.	1.0	7
56	External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. European Urology, 2020, 78, 138-142.	0.9	55
57	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of <sup>68</sup> Ga-PSMA and <sup>11</sup> C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections, Journal of Urology, 2020, 204, 296-302.	0.2	32
58	Open ureteroplasty with buccal mucosa graft for long proximal strictures: A good option for a rare problem. Investigative and Clinical Urology, 2020, 61, 316.	1.0	14
59	Reply by Authors. Journal of Urology, 2020, 204, 302-302.	0.2	0
60	The impact of perioperative complications on favorable outcomes after artificial urinary sphincter implantation for post-prostatectomy incontinence. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 632-639.	0.7	6
61	Editorial Comment. Journal of Urology, 2020, 204, 458-458.	0.2	0
62	Influence of the laser pulse shape in the treatment of stones in the upper urinary tract. Investigative and Clinical Urology, 2020, 61, 594.	1.0	5
63	Imaging modalities in synchronous oligometastatic prostate cancer. World Journal of Urology, 2019, 37, 2573-2583.	1.2	16
64	Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?. World Journal of Urology, 2019, 37, 243-251.	1.2	37
65	Extended followâ€up of the AdVance XP male sling in the treatment of male urinary stress incontinence after 48 months: Results of a prospective and multicenter study. Neurourology and Urodynamics, 2019, 38, 1973-1978.	0.8	20
66	Hereditary prostate cancer – Primetime for genetic testing?. Cancer Treatment Reviews, 2019, 81, 101927.	3.4	20
67	Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE). European Urology, 2019, 75, 692-693.	0.9	0
68	Benefits and Complications during the Stay at an Early Rehabilitation Facility after Radical Cystectomy and Orthotopic Ileum Neobladder Reconstruction. Urologia Internationalis, 2019, 103, 350-356.	0.6	5
69	Health-related quality of life after radical cystectomy and ileal orthotopic neobladder: effect of detailed continence outcomes. World Journal of Urology, 2019, 37, 2385-2392.	1.2	20
70	Re: Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients with High-risk Prostate Cancer with Rising Prostate-specific Antigen Levels After Primary Local Therapy A Randomized Clinical Trial. European Urology, 2019, 76, 405-406.	0.9	0
71	Aggressive variants of prostate cancer – Are we ready to apply specific treatment right now?. Cancer Treatment Reviews, 2019, 75, 20-26.	3.4	23
72	Validation of a High-End Virtual Reality Simulator for Training Transurethral Resection of Bladder Tumors. Journal of Surgical Education, 2019, 76, 568-577.	1.2	22

#	Article	IF	CITATIONS
73	Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?. European Urology Focus, 2019, 5, 114-116.	1.6	4
74	Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. European Urology, 2019, 76, 493-504.	0.9	111
75	Artificial Urinary Sphincter Cuff Size Predicts Outcome in Male Patients Treated for Stress Incontinence: Results of a Large Central European Multicenter Cohort Study. International Neurourology Journal, 2019, 23, 219-225.	0.5	13
76	Robotic-assisted Excision of Giant Prostatic Utricular Cysts: Technique, Outcomes and Follow-up. Surgical Technology International, 2019, 35, 43-47.	0.1	1
77	Longâ€ŧerm functional outcome analysis in a large cohort of patients after radical prostatectomy. Neurourology and Urodynamics, 2018, 37, 2263-2270.	0.8	15
78	Local treatment for metastatic prostate cancer: A systematic review. International Journal of Urology, 2018, 25, 390-403.	0.5	37
79	The TiLOOP® Male Sling: Did We Forejudge. Urologia Internationalis, 2018, 100, 216-221.	0.6	2
80	Combining anticancer drugs with osteoprotective agents in prostate cancer—A contemporary update. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 488-497.	0.8	0
81	Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 529.e11-529.e22.	0.8	31
82	How can we expand active surveillance criteria in patients with low―and intermediateâ€risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. BJU International, 2018, 122, 823-830.	1.3	27
83	Surgical High-risk Patients With ASAÂ≥ 3 Undergoing Radical Cystectomy: Morbidity, Mortality, and Predictors for Major Complications in a High-volume Tertiary Center. Clinical Genitourinary Cancer, 2018, 16, e1141-e1149.	0.9	21
84	The AdVance and AdVanceXP male sling in urinary incontinence: is there a difference?. World Journal of Urology, 2018, 36, 1657-1662.	1.2	21
85	Denervation versus pre―and postsynaptic muscle immobilization: Effects On acetylcholine―and muscleâ€specific tyrosine kinase receptors. Muscle and Nerve, 2017, 55, 101-108.	1.0	8
86	Perioperative patient education improves long-term satisfaction rates of low-risk prostate cancer patients after radical prostatectomy. World Journal of Urology, 2017, 35, 1205-1212.	1.2	18
87	Antibiotic Coating of the Artificial Urinary Sphincter (AMS 800): Is it Worthwhile?. Urology, 2017, 103, 179-184.	0.5	19
88	Postoperative upgrading of prostate cancer in men ≥75Âyears: a propensity score-matched analysis. World Journal of Urology, 2017, 35, 1517-1524.	1.2	17
89	Prognostic Value of the Preoperative Platelet-to-leukocyte Ratio for Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer. Clinical Genitourinary Cancer, 2017, 15, e915-e921.	0.9	16
90	Dramatic impact of blood transfusion on cancer-specific survival after radical cystectomy irrespective of tumor stage. Scandinavian Journal of Urology, 2017, 51, 130-136.	0.6	33

Alexander Kretschmer

#	Article	IF	CITATIONS
91	Prospective evaluation of health-related quality of life after radical cystectomy: focus on peri- and postoperative complications. World Journal of Urology, 2017, 35, 1223-1231.	1.2	20
92	Biomarkers in prostate cancer – Current clinical utility and future perspectives. Critical Reviews in Oncology/Hematology, 2017, 120, 180-193.	2.0	135
93	Surgical Treatment of Male Postprostatectomy Incontinence: Current Concepts. European Urology Focus, 2017, 3, 364-376.	1.6	40
94	Follow-up of high-risk bladder cancer—Is it safe to perform fluorescence endoscopy multiple times in the same patient?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 602.e19-602.e23.	0.8	6
95	Prognostic Features for Objectively Defined Urinary Continence after Radical Cystectomy and Ileal Orthotopic Neobladder in a Contemporary Cohort. Journal of Urology, 2017, 197, 210-215.	0.2	22
96	Risk Factors for Failure of Male Slings and Artificial Urinary Sphincters: Results from a Large Middle European Cohort Study. Urologia Internationalis, 2017, 99, 14-21.	0.6	34
97	36â€month data for the AdVance <scp>XP</scp> <sup>®</sup> male sling: results of a prospective multicentre study. BJU International, 2017, 119, 626-630.	1.3	76
98	Male Incontinence: The Etiology or Basis of Treatment. European Urology Focus, 2017, 3, 377-384.	1.6	20
99	Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients. Oncotarget, 2017, 8, 84180-84192.	0.8	41
100	Targeting Moderate and Severe Male Stress Urinary Incontinence With Adjustable Male Slings and the Perineal Artificial Urinary Sphincter: Focus on Perioperative Complications and Device Explantations. International Neurourology Journal, 2017, 21, 109-115.	0.5	17
101	Prognostic features for quality of life after radical cystectomy and orthotopic neobladder. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 1109-1120.	0.7	32
102	AdVanceXP male sling: 2-year results of a multicentre study. World Journal of Urology, 2016, 34, 1025-1030.	1.2	26
103	Complications and Short-Term Explantation Rate Following Artificial Urinary Sphincter Implantation: Results from a Large Middle European Multi-Institutional Case Series. Urologia Internationalis, 2016, 97, 205-211.	0.6	27
104	Editorial Comment to Treatmentâ€related neuroendocrine prostate cancer resulting in Cushing's syndrome. International Journal of Urology, 2016, 23, 1041-1042.	0.5	0
105	Efficacy and safety of the ZSI375 artificial urinary sphincter for male stress urinary incontinence: lessons learned. World Journal of Urology, 2016, 34, 1457-1463.	1.2	23
106	Evaluation and Management of Postprostatectomy Incontinence: A Systematic Review of Current Literature. European Urology Focus, 2016, 2, 245-259.	1.6	84
107	Midâ€ŧerm outcomes after AdVanceXP male sling implantation. BJU International, 2016, 118, 458-463.	1.3	28
108	68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. European Urology, 2016, 70, 553-557.	0.9	248

Alexander Kretschmer

#	Article	IF	CITATIONS
109	Risk factors for artificial urinary sphincter failure. World Journal of Urology, 2016, 34, 595-602.	1.2	45
110	Long-term Outcome of the Retrourethral Transobturator Male Sling After Transurethral Resection of the Prostate. International Neurourology Journal, 2016, 20, 335-341.	0.5	17
111	MP88-09 ADVANCE XP MALE SLING: OUTCOME OF A PROSPECTIVE MULTICENTER STUDY. Journal of Urology, 2015, 193, .	0.2	1
112	Efficacy and Complications of the Adjustable Sling System ArgusT for Male Incontinence: Results of a Prospective 2-Center Study. Urology, 2015, 85, 316-320.	0.5	44
113	Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer after Radical Prostatectomy. Journal of Urology, 2015, 193, 484-490.	0.2	66
114	Surgical learning curve for open radical prostatectomy: Is there an end to the learning curve?. World Journal of Urology, 2015, 33, 1721-1727.	1.2	16
115	Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS). World Journal of Urology, 2015, 33, 917-922.	1.2	14
116	AdVance and AdVance XP slings for the treatment of post-prostatectomy incontinence. World Journal of Urology, 2015, 33, 145-150.	1.2	29
117	The effect of BMI on clinicopathologic and functional outcomes after open radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 297-302.	0.8	25
118	MP33-10 THE ADVANCEXP MALE SLING: RESULTS OF A PROSPECTIVE MULTICENTER STUDY. Journal of Urology, 2014, 191, .	0.2	1
119	Electromyographic Permutation Entropy Quantifies Diaphragmatic Denervation and Reinnervation. PLoS ONE, 2014, 9, e115754.	1.1	2
120	The Added Value of Baseline Health-Related Quality of Life in Predicting Survival in High-Risk Prostate Cancer Patients Following Radical Prostatectomy. Journal of Urology, 0, , .	0.2	0